Torsemide

# torsemide ## Overview - **Classification**: Loop Diuretic - **Mechanism**: Inhibits the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water. ## Primary Indications 1. **Edema associated with heart failure**: Management of fluid overload. 2. **Edema associated with renal disease**: Management of fluid retention. 3. **Edema associated with hepatic cirrhosis**: Management of ascites and edema. 4. **Hypertension**: As monotherapy or in combination. ## Adult Dosing ### Standard Dosing **Edema (CHF, Renal, Hepatic)** - **Dose**: Initial **10 mg** or **20 mg** - **Frequency**: Once daily - **Route**: Oral (PO) or Intravenous (IV) - **Titration**: May double dose up to **200 mg** once daily if needed. - **Special considerations**: IV for acute settings, switch to PO when stable. **Hypertension** - **Dose**: Initial **5 mg** - **Frequency**: Once daily - **Route**: Oral (PO) - **Titration**: May increase to **10 mg** once daily after 4-6 weeks if needed. ### Dose Adjustments - **Renal Impairment**: No specific initial dose adjustment for mild-moderate. For severe renal impairment, higher doses (e.g., **20 mg** to **200 mg** daily) may be required. Monitor closely. - **Hepatic Impairment**: Use with caution. Consider lower doses and monitor for electrolyte imbalances and hepatic encephalopathy. - **Elderly Patients**: No specific dose adjustment generally needed. Start at lower end of dosing range. Monitor for dehydration and electrolyte abnormalities. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Limited data. Initial **0.05-0.2 mg/kg**. - **Frequency**: Once daily. - **Maximum**: **0.2 mg/kg/day**. - **Special Notes**: Use with extreme caution. Closely monitor fluid status, electrolytes, and renal function. Furosemide generally preferred. ### Infants (1-12 months) - **Dose**: Limited data. Initial **0.1-0.2 mg/kg**. - **Frequency**: Once daily. - **Maximum**: **0.4 mg/kg/day**. - **Special Notes**: Monitor for dehydration and electrolyte imbalances (hypokalemia, hyponatremia). ### Children (1-12 years) - **Dose**: Limited data. Initial **0.1-0.2 mg/kg**. - **Frequency**: Once daily. - **Maximum**: Up to **0.4 mg/kg/day**. Max single dose **20 mg**. Max daily dose typically **200 mg** for severe edema. - **Special Notes**: Closely monitor fluid status and electrolytes. ### Adolescents (13-18 years) - **Dose**: Approach adult dosing. Initial **5 mg** to **10 mg**. - **Frequency**: Once daily. - **Maximum**: **200 mg** once daily for severe edema; **10 mg** once daily for hypertension. - **Special Notes**: Monitor closely, especially if starting with higher doses for edema. ## Safety Information ### Contraindications - **Absolute**: Anuria (complete lack of urine production). - **Absolute**: Hypersensitivity to torsemide or sulfonylureas. - **Relative**: Hepatic coma and pre-coma states. - **Relative**: Severe electrolyte depletion (e.g., severe hypokalemia, hyponatremia). ### Common Adverse Effects - **Very Common (>10%)**: Headache, dizziness, excessive urination (polyuria). - **Common (1-10%)**: Nausea, diarrhea, constipation, dyspepsia, fatigue, cough, rhinitis, hyperglycemia, hypokalemia, hypomagnesemia, hyperuricemia, ototoxicity (high doses/rapid IV). - **Serious but Rare**: Severe dermatologic reactions (e.g., SJS, TEN), blood dyscrasias, hepatic encephalopathy, acute kidney injury. ### Key Drug Interactions - **Aminoglycoside antibiotics/Cisplatin**: Increased risk of ototoxicity and nephrotoxicity. Avoid concurrent use. - **NSAIDs (e.g., ibuprofen)**: May reduce diuretic and antihypertensive effects of torsemide. Monitor BP and edema. - **Digoxin**: Risk of digoxin toxicity increased with torsemide-induced hypokalemia. Monitor K+ levels and digoxin levels. - **Lithium**: Torsemide decreases renal excretion of lithium, increasing lithium levels and toxicity. Reduce lithium dose, monitor levels closely. - **Antihypertensives**: Additive hypotensive effect. Monitor blood pressure. - **Oral Hypoglycemics**: Torsemide may increase blood glucose. Monitor blood glucose, adjust antidiabetic meds if needed. - **Warfarin**: May potentiate anticoagulant effect. Monitor INR. ## Monitoring & Follow-up - **Before Treatment**: Baseline electrolytes (Na, K, Mg, Ca), renal function (BUN, Cr), uric acid, glucose, blood pressure, weight. - **During Treatment**: - **Electrolytes**: Regularly (e.g., weekly initially, then monthly). - **Renal function**: Periodically (e.g., monthly). - **Blood pressure/Weight**: Daily/weekly depending on indication. - **Fluid balance**: Intake and output, signs of dehydration/overload. - **Clinical Signs**: Monitor for dizziness, muscle cramps, weakness, confusion (electrolyte imbalance), hearing changes. ## Clinical Pearls - 💡 **Timing**: Administer in the morning to prevent nocturia and sleep disturbance. - 💡 **Potency**: **20 mg** torsemide is approximately equipotent to **40 mg** furosemide orally. - 💡 **Bioavailability**: Has excellent oral bioavailability (~80-90%), making IV to PO conversion straightforward. - 💡 **Electrolytes**: Educate patients on symptoms of electrolyte imbalance. Consider potassium-rich foods or supplementation. - 💡 **Sulfonamide**: Patients with a sulfonamide allergy are typically NOT cross-reactive with torsemide, but use with caution in severe reactions. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.